Longevity & Anti-Aging: P11-4 / Curodont Repair (Self-Assembling Peptide — Biomimetic Enamel Remineralization)

Why an eleven-amino acid peptide from Switzerland is initiating a paradigm shift in caries therapy — from fluoride surface protection to true crystal repair

Dental health is one of the most underestimated pillars of healthy aging: caries, periodontitis, and tooth loss are epidemiologically correlated with cardiovascular events, cognitive decline, and shortened healthy lifespan. P11-4 (trade name Curodont™ Repair, manufacturer: Credentis AG, Windisch, Switzerland — now part of verox) is the first self-assembling peptide (SAP) to be broadly used in dental practice that does not merely protect the enamel surface but biologically rebuilds the defective hydroxyapatite structure of initial carious lesions. Evidence from at least seven randomized controlled trials, one network meta-analysis, and several systematic reviews shows: P11-4 reduces white spot lesions (WSL) significantly more than fluoride monotherapy — and importantly, in the depth of the lesion, not only at the surface.

Background: White Spot Lesions and Initial Caries

The white spot lesion (WSL) is the clinical early stage of enamel caries. It arises when the pH of the dental biofilm repeatedly drops below the critical value of approximately 5.5 due to bacterial acid production — typically after intake of fermentable carbohydrates. The dominant species in plaque, Streptococcus mutans and Lactobacillus, metabolize sugars to lactic acid, leading to demineralization of the enamel: calcium and phosphate ions leave the hydroxyapatite structure, the porosity of the enamel increases, and the characteristic chalky-white, opaque spots appear.

Epidemiologically, WSL are extremely common: approximately 23–95% of orthodontic patients develop post-orthodontic demineralizations, depending on oral hygiene and treatment duration. In the general population, about one in four adults shows at least one initial carious lesion. Particularly at risk are patients undergoing fixed multibracket therapy — the brackets complicate cleaning, create plaque retention sites, and alter biofilm composition.

A white spot lesion is in principle reversible as long as the superficial enamel layer is intact (so-called non-cavitated lesion). In this phase, demineralization and remineralization compete — and this is exactly where P11-4 comes in. The central challenge of conventional fluoride therapy: fluoride remineralizes mainly at the surface and preferentially forms fluoroapatite (instead of hydroxyapatite), which is more acid-stable but biologically not identical to the natural enamel mineral. The core of the lesion remains porous.

P11-4: Sequence, Chemistry, and the pH Switch

The peptide P11-4 (also written P(11)-4) consists of 11 amino acids. The most commonly cited sequence in the literature is CH₃CO-QQRFEWEFEQQ-OH (alternatively: ACEGAAAKEACG in a shorter representation). It is a short, synthetically produced peptide that exists in aqueous solution at pH values below 7 as an unfolded monomer — that is, in the form in which it is applied from the application syringe onto the tooth.

The chemical sophistication lies in a pH-dependent folding switch:

• At pH < 7 (acidic, solution): Glutamate and aspartate side chains are protonated, the peptide remains soluble and monomeric.
• At pH > 7 (alkaline, enamel surface): The carboxylate groups deprotonate, the electrostatic repulsion is removed, and the peptide folds into an antiparallel β-sheet structure.
• Aggregation: Multiple β-sheet monomers assemble into a three-dimensional fiber network (scaffold) with hydrophilic and hydrophobic domains — an amyloid-like self-assembly pattern typical of proteins.

The resulting network forms on the enamel surface and within the micropores of the demineralized lesion a biomimetic matrix that is structurally similar to the natural enamel matrix proteins (amelogenin, ameloblastin) that guide hydroxyapatite crystallization during tooth development. Thus P11-4 mimics an embryonic biomineralization process — hence the term biomimetic.

Mechanism of Action: Self-Assembly, Ion Recruitment, and Hydroxyapatite Nucleation

The biological effect of P11-4 unfolds in several interconnected steps that are documented in in vitro studies and in clinical application.

1. Diffusion into the Lesion

In the slightly acidic environment of the attacked enamel surface (pH ≈ 5.5–6.5), P11-4 remains monomeric and small enough to diffuse into the pores and microcracks of the demineralized lesion — typical lesion depths range from 50–300 µm. On contact with the more alkaline interior of the enamel (pH ≈ 7.0–7.5), the peptide spontaneously folds into the fiber network.

2. Self-Assembly into a 3D Scaffold

Within minutes, P11-4 forms a hierarchically organized network of β-sheet fibrils that three-dimensionally spans the lesion. The network exhibits a periodic arrangement of hydrophilic (water-binding) and hydrophobic domains — an architecture that selectively binds calcium and phosphate ions and presents them at high local concentration.

3. Ion Recruitment from Saliva

The negatively charged carboxylate groups of the peptide scaffold act as an ion exchanger: they recruit Ca²⁺ ions from the surrounding saliva and from the lesion fluid. These ions in turn electrostatically bind phosphate anions. This creates a local supersaturation of calcium and phosphate directly at the scaffold.

4. Nucleation and Directed Crystal Growth

On the surface of the peptide fiber network, new hydroxyapatite crystals (HA) nucleate — and crucially, along the c-axis, that is, in the same crystallographic orientation as natural enamel. This is the decisive difference from fluoride: fluoroapatite grows uncontrollably at the surface; P11-4-nucleated hydroxyapatite grows structurally correctly in the depth of the lesion.

5. Depth Remineralization

Over weeks to months, the lesion is filled from the inside out with new, crystallographically correct hydroxyapatite. The microporosity decreases, the light scattering of the lesion diminishes — the white opacity fades, clinically visible. This process is called biomimetic depth remineralization — and it is the reason why P11-4 shows significantly better results than fluoride monotherapy in several RCTs.

Clinical Evidence: Seven RCTs and Meta-Analyses

The evidence base for P11-4 is remarkably good for a novel dental material. As of August 2026, at least seven randomized controlled trials, several systematic reviews, and one network meta-analysis are available.

1. 12-Month RCT on White Spot Lesions (J Dent 2026)

One of the methodologically most convincing studies was published in 2026 in the Journal of Dentistry (PMID 41412271): a 12-month RCT on the clinical evaluation of biomimetic scaffolds in WSL. Adults with active, non-cavitated white spot lesions were enrolled. The primary endpoint was the change in WSL area and ICDAS score over 12 months. Result: The P11-4 group showed a significantly greater reduction in lesion area compared to fluoride varnish and untreated controls — the effect was measurable as early as 3 months and remained stable throughout the observation period. The study confirms P11-4 as a clinically effective monotherapy for active WSL.

2. Triple-Blind RCT in Multibracket Therapy (BMC Oral Health 2026)

A prospective, triple-blind RCT (PMID 41514234) investigated the protective effect of P11-4 against demineralization during fixed orthodontic treatment. Patients were randomized before bracket insertion into two groups: a single P11-4 application vs. placebo. After completion of multibracket therapy, the incidence and area of newly developed WSL were measured. The P11-4 group showed a significantly lower incidence of post-orthodontic demineralizations — a clinically highly relevant finding, as orthodontic WSL are among the most common and psychosocially burdensome side effects of bracket therapy.

3. Curodont Repair Fluoride Plus in Primary Teeth (J Evid Based Dent Pract 2025)

An RCT specifically for pediatric dentistry (PMID 40716822) compared an intensive application protocol of Curodont Repair Fluoride Plus with MI Varnish (GC, Japan) and Duraphat Varnish (Colgate-Palmolive) for white spot lesions in primary teeth. Result: Curodont Repair Fluoride Plus showed a higher success rate in visual lesion reduction and achieved complete remission in a significantly higher proportion of initially active lesions than both fluoride comparators. This study is methodologically relevant because it documents efficacy in the vulnerable patient group of children.

4. P11-4 vs. Arginine-Fluoride and TCP-Fluoride (BDJ Open 2025)

A four-arm RCT (PMID 40715066) compared the remineralization ability of P11-4 (Curodont Repair), 2% arginine-enriched sodium fluoride (Colgate-Palmolive), functionalized tri-calcium-phosphate fluoride varnish, and a control group directly in WSL patients. Primary endpoints: laser fluorescence-based measurement of mineral content recovery (Diagnodent) and visual ICDAS scoring. Result: P11-4 performed significantly better on both endpoints than both fluoride formulations — a direct head-to-head comparison that underscores the differential advantage of P11-4.

5. Network Meta-Analysis (BMC Oral Health 2023)

The most comprehensive network meta-analysis on WSL therapies to date (PMID 38195439) evaluated 36 RCTs with over 2,000 patients and compared different remineralization protocols directly and indirectly. Result: The combination of P11-4 + fluoride varnish (so-called FV + P11-4) was the top therapy with the highest probability of success — followed by CPP-ACP (Tooth Mousse) and fluoride monotherapy. P11-4 is thus first choice in the evidence-based hierarchy of WSL treatments — above all established fluoride protocols.

6. Systematic Review P11-4 vs. Fluoride (Cureus 2025)

A dedicated systematic review (PMID 41306178) compared in 2025 the remineralization potential of self-assembling peptides versus fluoride agents in WSL. Eleven RCTs and 4 in vitro studies with standardized methodological assessment were included. Conclusion: P11-4 shows consistently superior results in reduction of lesion area and laser fluorescence measurement. The reviewers, however, emphasize the need for longer-term studies (> 24 months) to validate the durability of the effect.

7. Comprehensive Review on Peptide Remineralization (Medicina 2026)

A comprehensive review article in the journal Medicina (Kaunas) (PMID 42356099) summarizes the entire class of peptide-based remineralization strategies — P11-4, P(113) (P-113 is an antimicrobial peptide from histatin-5 used in mouthwashes against Streptococcus mutans, PMID 39347072), and newer fluorinated peptide variants. The review classifies P11-4 as the currently most clinically advanced self-assembling peptide in dentistry.

8. Further Supporting Studies

A 2026 BMC Oral Health study (PMID 41832454) investigated the effect of P11-4 on post-bleaching microhardness and color stability — relevant for the increasing number of aesthetically motivated bleaching patients. An ex vivo study (PMID 40683232) showed additional dentin remineralization effects in obese children, a hint at possible systemic modulators of P11-4 action. An in vitro laser confocal microscopy study (PMID 40524587) quantified the infiltration depth of P11-4 compared to CPP-ACFP (MI Varnish) and fluorinated peptide variants — P11-4 achieved the deepest penetration into artificial enamel lesions. An in vitro study (PMID 41960487) additionally examined the effect of diode laser pre-treatment on P11-4 remineralization — a possible future combination approach.

Comparison Table: P11-4 vs. Established Remineralization Protocols

Sources: PMID 38195439 (network meta-analysis), 41306178, 41412271, 40715066, 41514234, 42356099. P-113 antimicrobial profile in Journal of Dental Sciences 2024.

Regulatory Status USA and EU

USA: P11-4 (Curodont Repair) received 510(k) clearance from the US Food and Drug Administration (FDA) — the approval category for medical devices that are demonstrated to be "substantially equivalent" to an already marketed product. It is marketed in the USA through dental distributors; application takes place exclusively in the dental practice (in-office), not as an OTC product.

EU: P11-4 is CE-marked as a Class I (or IIa, depending on product variant) medical device and can be legally marketed in all EU member states and in Switzerland. The manufacturer is Credentis AG (Windisch, Switzerland), which became part of the verox Group in 2018. Distribution partners in Germany and Switzerland are various dental depots.

International: P11-4 is also approved or available in Canada, the United Kingdom, Australia, and several Asian markets.

Side Effects & Safety

The safety profile of P11-4 is excellent — consistent across all available clinical studies:

• No systemic side effects: P11-4 is not absorbed, remains locally on the tooth surface, and is mechanically abraded or removed during brushing over time.
• Local tolerability: In none of the published RCTs were significant adverse events reported. Occasionally mild, transient taste irritations immediately after application.
• No documented allergies: P11-4 contains no human allergens, no proteins of animal origin (no casein like CPP-ACP, no bovine or porcine components), and is fully synthetic.
• Pregnancy and breastfeeding: Classified as safe due to the lack of systemic absorption, however no formal studies — as is the case with almost all dental materials.
• Children: Documented as safe and well-tolerated in RCTs on children with primary tooth WSL (PMID 40716822).
• No fluoride concerns: In contrast to high-dose fluoride varnish (Duraphat contains 5% NaF, approximately 22,600 ppm F⁻), P11-4 involves no fluoride uptake and no risk of dental fluorosis in children.

Contraindications: Known hypersensitivity to any of the ingredients (extremely rare). No absolute contraindications.

Practical Implications

As of August 2026, P11-4 is available in Germany, Austria, and Switzerland through specialized dental and orthodontic practices. The practical implications for interested patients:

Application

Application is performed non-invasively in the dental practice:

1. Professional tooth cleaning and drying of the lesion
2. Etching of the enamel surface with 35% phosphoric acid (optional, about 5 seconds) to open the lesion pores
3. Application of P11-4 solution with a microbrush (brush application)
4. 5 minutes exposure time — the peptide assembles into the scaffold during this time
5. Removal of excess, rinse

The treatment takes approximately 15–20 minutes per quadrant, is painless, and requires no anesthesia. As a rule, a single application is sufficient — follow-up examinations at 3, 6, and 12 months are recommended.

Cost (as of 2026)

• USA: USD 150–250 per application and tooth, depending on the practice and lesion size. Generally not reimbursed by health insurance (esthetic dentistry).
• EU/Germany: approximately EUR 100–200 per tooth. No regular reimbursement by statutory health insurance (GOZ billing as "extended fissure sealing" or analogous position). Private supplementary insurances partially cover the cost.

Who is P11-4 particularly suitable for?

• Orthodontic patients with active or completed bracket therapies and post-orthodontic WSL
• Patients with initial enamel caries on smooth surfaces (buccal, cervical) that do not yet require invasive treatment
• Patients with enamel hypomineralization (e.g., molar-incisor hypomineralization MIH in children)
• Post-bleaching patients with temporarily reduced enamel hardness or incipient demineralization
• Patients with dentin hypersensitivity — studies suggest reduced hypersensitivity after P11-4 application (PMID 40683232)
• Early childhood caries — as a minimally invasive alternative to invasive restoration

Outlook: Where is P11-4 Research Heading?

P11-4 research is developing in several exciting directions:

1. Dentin Hypersensitivity

Initial clinical observations suggest that P11-4 can also treat exposed tooth necks by occluding the dentin tubules. The mechanism would be analogous to enamel remineralization: the peptide scaffold assembles within the open dentin tubules and forms a mineralized barrier. An RCT on this is currently underway (as of 2026).

2. Pulp Regeneration and Dentin-Pulp Complex

Preclinical work is investigating whether P11-4 derivatives could serve as scaffold structures for regeneration of the dentin-pulp complex — for example, after pulpitis or in deep cavities. Initial in vitro data show that modified P11-4 variants support the migration and differentiation of dental stem cells (PMID 42356099).

3. Combination with Bioglass

Bioglass particles (e.g., Bioactive Glass 45S5) release calcium and phosphate ions on contact with saliva and create an alkaline environment — both favorable for P11-4 action. Synergistic formulations of P11-4 and bioglass are currently being evaluated in the preclinical pipeline.

4. Fluorinated P11-4 Variants

An in vitro study (PMID 40524587) investigated novel fluorinated self-assembling peptides that combine the P11-4 backbone with fluoroapatite formation. This "best-of-both-worlds" strategy targets an even faster and more stable remineralization.

5. Antimicrobial Peptides as Adjuvants

The combination of P11-4 with antimicrobial peptides such as P-113 (a 12-AA fragment of histatin-5) is another research direction. P-113 reduces Streptococcus mutans and thus acid production (PMID 39347072); P11-4 repairs the demineralization that has already occurred. Theoretically, both peptides could act synergistically — analogous to the anti-bacterial + regenerative concept.

6. Larger and Longer RCTs

The current evidence base is solid, but the follow-up periods of most RCTs are 6–12 months. Longer studies (> 24 months) with larger cohorts are needed to demonstrate the durability of remineralization. The research landscape is active here, and it is likely that further Phase-3-equivalent studies will be published in the next 2–3 years.

Conclusion

P11-4 (Curodont Repair) is a paradigm shift in non-invasive caries therapy. The synthetic 11-amino acid peptide mimics the embryonic biomineralization process, assembles on the demineralized enamel surface into a β-sheet scaffold, and recruits calcium and phosphate ions for depth remineralization along the natural hydroxyapatite c-axis. The clinical evidence from at least seven RCTs, one network meta-analysis (PMID 38195439), and several systematic reviews (e.g., PMID 41306178, PMID 42356099) shows consistently: P11-4 reduces white spot lesions significantly more than fluoride monotherapy, is safe in application, and is particularly suitable for post-orthodontic demineralizations, initial enamel caries, and pediatric patients.

For longevity medicine, P11-4 is indirectly relevant: dental health correlates with systemic health, and preservation of natural dentition into old age is a reliable marker of healthy aging. A minimally invasive, biological procedure that repairs tooth structure rather than removing it fits seamlessly into the concept of body preservation — the philosophy of maintaining the body's own structures as long as possible before prosthetic interventions become necessary.

The limitations must be honestly named: P11-4 works only on initial, non-cavitated lesions, is not suitable for home application, and is not regularly reimbursed in most healthcare systems. Most studies are 6–12 months long; long-term data beyond 24 months are limited. Those interested in the therapy should discuss this with a specialized dental or orthodontic practice — and understand a P11-4 application as a supplement to consistent oral hygiene and regular professional tooth cleaning, not as a replacement.

The coming years will show whether P11-4 variants will open up new application fields in dentin hypersensitivity, pulp regeneration, and combination with antimicrobial peptides — and whether the underlying biomimetic self-assembly technology will also find application in other tissues (bone, cartilage). P11-4 is already more than a dental product today: it is an early, clinically validated representative of a new generation of peptide-based biomineralization therapeutics.